Echocardiographic evaluation of cardiac amyloidosis

Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study

Observational Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05760287

This study is testing new heart imaging techniques to see if they can help tell cardiac amyloidosis apart from other heart problems and check how well tafamidis treatment can improve heart damage in patients.

Quick facts

Study typeObservational
Enrollment255 (estimated)
Ages18 Years and up
SexAll
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other
Locations1 site (Roma, RM)
Trial IDNCT05760287 on ClinicalTrials.gov

What this trial studies

This observational study focuses on patients diagnosed with cardiac amyloidosis at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. It aims to utilize advanced echocardiographic techniques, including two- and three-dimensional speckle-tracking analysis, to differentiate cardiac amyloidosis from other similar heart conditions. Additionally, the study will assess the reversibility of myocardial damage in response to tafamidis treatment and explore new echocardiographic predictors of adverse cardiovascular outcomes.

Who should consider this trial

Good fit: Ideal candidates are patients diagnosed with cardiac amyloidosis who meet the inclusion criteria set by the European Society of Cardiology.

Not a fit: Patients who do not have cardiac amyloidosis or those who decline participation will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the diagnostic accuracy and treatment monitoring for patients with cardiac amyloidosis.

How similar studies have performed: While this approach is observational, similar studies utilizing advanced echocardiographic techniques have shown promise in improving diagnostic capabilities for cardiac conditions.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit.

Exclusion Criteria:

* missing data
* decline to the study participation

Where this trial is running

Roma, RM

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Cardiac Amyloidosisechocardiographyleft ventricle
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.